Original ResearchPublished 12 December 2025A real-world disproportionality analysis of roflumilast using the US food and drug administration adverse event reporting system dataBaiqing Huang · Yirou Ma · Wenli Wang · Shaorui Gu · Xisheng WangFrontiers in Drug Safety and Regulationdoi 10.3389/fdsfr.2025.1721656
PerspectivePublished 25 November 2025The role of MedDRA in global pharmacovigilance and public health during COVID-19: pandemic preparedness and responseBrian O’Hare · Heba Ibrahim · Patrick RevelleFrontiers in Drug Safety and Regulationdoi 10.3389/fdsfr.2025.1607642
